⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Registry of Participants With Prostate Cancer in Asia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Registry of Participants With Prostate Cancer in Asia

Official Title: A Multicenter, Prospective, Longitudinal Registry of Patients With Prostate Cancer in Asia

Study ID: NCT02546908

Interventions

No Intervention

Study Description

Brief Summary: The purpose of this study is to document prostate cancer (PC) management including diagnosis, prognosis, treatment, and care in real-world practice.

Detailed Description: This is a multicenter (when more than one hospital or medical school team work on a medical research study), prospective (observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group), longitudinal, observational registry (clinical study in which participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to specific interventions \[as in an interventional study\])of PC participants. The following 3 participant cohorts will be enrolled: high-risk localized PC, non-metastatic biochemically recurrent PC, and metastatic PC. This is an observational study and treatment decisions and clinical management of participants will follow routine clinical practice. Medical care given to participants will not be influenced by participation in the study. Enrolled participants will be prospectively followed throughout their course of treatment, during which data on PC treatment, clinical progression, and outcomes (including death) will be collected. At the end of registry medical resource utilization (MRU) will also be collected. The maximum observational period will be 5 years. Safety will be monitored throughout the study for participants being treated with JNJ products.

Eligibility

Minimum Age: 21 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: MALE

Healthy Volunteers: No

Locations

, Beijing, , China

, Guangzhou, , China

, Hangzhou, , China

, Shanghai, , China

, Shenyang, , China

, Sichuan, , China

, Su Zhou, , China

, Wuhan, , China

, Bangalore, , India

, Delhi, , India

, Mumbai, , India

, New Delhi, , India

, Chiba, , Japan

, Hirosaki, , Japan

, Ikoma, , Japan

, Kobe, , Japan

, Koshigaya, , Japan

, Matsuyama, , Japan

, Osaka-Sayama, , Japan

, Suita, , Japan

, Seoul, , Korea, Republic of

, Kuala Lumpur N/a, , Malaysia

, Kuala Lumpur, , Malaysia

, Kuching, , Malaysia

, Pulau Pinang, , Malaysia

, Singapore, , Singapore

, Kaohsiung, , Taiwan

, Tainan, , Taiwan

, Taipei, , Taiwan

, Bangkok, , Thailand

, Chiang Mai, , Thailand

, Songkla, , Thailand

Contact Details

Name: Janssen Research & Development, LLC Clinical Trial

Affiliation: Janssen Research & Development, LLC

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: